JAK Inhibition by Baricitinib in Diabetic Kidney Disease JAK Inhibition by Baricitinib in Diabetic Kidney Disease
How does treatment with baricitinib impact albuminuria and diabetic kidney disease progression in patients with type 2 diabetes?Nephrology Dialysis Transplantation
ConclusionsThe age-standardized annual incidence of ESKD increased in Australia from 2002 to 2013 for nonindigenous people with type 2 diabetes but was stable for people with type 1 diabetes. Efforts to prevent the development of ESKD, especially among indigenous Australians and those with early-onset type 2 diabetes, are warranted.
(Baker Heart and Diabetes Institute) A study of more than 1.3 million Australians with diabetes has found that kidney failure is increasing in people with type 2 diabetes aged under 50 years, leading to reduced quality of life and placing growing demand on the country's kidney dialysis and transplantation services.
Is dapagliflozin an effective therapeutic option for patients with type 2 diabetes and chronic kidney disease? How does it impact clinical outcomes in these patients?Nephrology Dialysis Transplantation
AI-powered kidney disease and transplant management diagnostic developer RenalytixAI said this week it completed an $29 million initial public offering on the London Stock Exchange’s Alternative Investment Market. The company was formed through an exclusive license with Mount Sinai Health Systems, who also acted as a development collaborator. The groups have been collaborating since May this year, the company said. “We’re thrilled to partner with RenalytixAI to develop much-needed prognostics and diagnostics that address the critical, unmet need of patients with high-risk of kidney disease. Mount Sinai&rs...
This study aims to specify the epidemio-logical, clinical, and biological characteristics of diabetic disease, chronic kidney disease (CKD), and comorbidities at the initiation of HD and investigate factors associated with mortality during the dialysis period. We retrospectively analyzed the outcome of diabetic patients who were initiated on HD from 2007 to 2012 at the Rabta Hospital of Tunis. During the follow-up period, all morbid events and deaths were recorded. Univariate analysis and multivariate analysis were performed to identify risk factors associated with mortality in our population. The study population included...
AbstractPurpose of ReviewTrimethylamine N-oxide (TMAO) is a gut microbiota-dependent metabolite produced from choline and phosphatidylcholine. Trimethylamine N-oxide was found associated with enhanced atherosclerosis and thrombosis in vitro and in vivo. We summarized available clinical studies which investigated TMAO ’s role in predicting prognostic outcomes, including mortality, in patients with cardiovascular diseases.Recent FindingsIn chronic kidney disease cohorts, higher TMAO levels were significantly associated with higher mortality from 1.18 to 4.32 folds. Higher TMAO levels were not significantly associated w...
Our patient is a 60-year-old female with a past medical history significant for diabetes mellitus type 2, smoking, anal cancer status-post transrectal excision with no evidence of recurrence or metastasis, rheumatoid arthritis, systemic lupus erythematosus and end-stage renal disease (ESRD) on hemodialysis (HD). She had progressive chronic kidney disease for approximately 25 years, ultimately starting HD 3 years prior to this evaluation. She presented to the urology department for evaluation prior to kidney transplantation.
CONCLUSIONS: Mortality risk is higher for patients with incident ESKD commencing dialysis who also have type 2 diabetes than for patients without diabetes, particularly among patients under 50 years of age, and the risk was more pronounced in patients for whom ESKD was attributed to diabetic nephropathy. PMID: 30332936 [PubMed - as supplied by publisher]
ConclusionThe results from the VERTIS-CV trial will define the CV and renal safety and efficacy of ertugliflozin in patients with T2DM and ASCVD.ClinicalTrials.gov identifier: NCT01986881
ConclusionsIn the past decade, the incidence of dialysis has stabilized in both the general population and in diabetics in whom it remains far higher by comparison. Also mortality rates are higher, with a worse prognosis for T1DM. Diabetes poses a barrier to allotransplantation, and efforts should be made to overcome this limitation.